The estimated Net Worth of Tina Susan Nova is at least $3.78 Million dollars as of 26 August 2020. Tina Nova owns over 17,300 units of Arena Pharmaceuticals Inc stock worth over $3,387,261 and over the last 20 years he sold ARNA stock worth over $0. In addition, he makes $395,133 as Independent Chairman of the Board at Arena Pharmaceuticals Inc.
Sign up
Tina Nova ARNA stock SEC Form 4 insiders trading
Tina has made over 3 trades of the Arena Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 17,300 units of ARNA stock worth $313,649 on 26 August 2020.
The largest trade he's ever made was exercising 35,000 units of Arena Pharmaceuticals Inc stock on 14 April 2014 worth over $164,500. On average, Tina trades about 1,092 units every 47 days since 2004. As of 26 August 2020 he still owns at least 33,876 units of Arena Pharmaceuticals Inc stock.
You can see the complete history of Tina Nova stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Tina Nova biography
Dr. Tina Susan Nova Ph.D. serves as Independent Chairman of the Board of the Company. She has served as a member of our Board of Directors since September 2004 and as Chair of the Board since June 2016. Dr. Nova previously served as the Board’s lead independent director from June 2015 to June 2016. Dr. Nova has served as President and Chief Executive Officer of Decipher Biosciences, Inc. (formerly GenomeDx, Inc.), a molecular diagnostics company focused in prostate cancer, since September 2018. Dr. Nova served as President and Chief Executive of Molecular Stethoscope, Inc. from September 2015 to August 2018. Dr. Nova served as Senior Vice President and General Manager of Illumina Inc.’s oncology business unit from July 2014 to August 2015. Dr. Nova was a co-founder of Genoptix, Inc., a medical laboratory diagnostics company, and served as its President from 2000 to April 2014. Dr. Nova also served as the Chief Executive Officer of Genoptix and as a member of its board of directors from 2000 until Novartis AG acquired Genoptix in March 2011. Dr. Nova was a co-founder of Nanogen, Inc., a provider of molecular diagnostic tests, and she served as its Chief Operating Officer and President from 1994 to 2000. Dr. Nova served as Chief Operating Officer of Selective Genetics, a biotechnology company, from 1992 to 1994, and in various director-level positions with Ligand Pharmaceuticals Incorporated, a drug discovery and development company, from 1988 to 1992, most recently as Executive Director of New Leads Discovery. Dr. Nova has also held various research and management positions with Hybritech, Inc., a former subsidiary of Eli Lilly & Company, a pharmaceutical company. Dr. Nova serves as a member of the board of directors of Veracyte, Inc., a diagnostics company, and OpGen, Inc., an infection prevention and treatment company.
What is the salary of Tina Nova?
As the Independent Chairman of the Board of Arena Pharmaceuticals Inc, the total compensation of Tina Nova at Arena Pharmaceuticals Inc is $395,133. There are 8 executives at Arena Pharmaceuticals Inc getting paid more, with Amit Munshi having the highest compensation of $8,931,400.
How old is Tina Nova?
Tina Nova is 66, he's been the Independent Chairman of the Board of Arena Pharmaceuticals Inc since 2017. There are 2 older and 13 younger executives at Arena Pharmaceuticals Inc. The oldest executive at Arena Pharmaceuticals Inc is Garry Neil, 67, who is the Independent Director.
What's Tina Nova's mailing address?
Tina's mailing address filed with the SEC is C/O EXAGEN INC., 1261 LIBERTY WAY, VISTA, CA, 92081.
Insiders trading at Arena Pharmaceuticals Inc
Over the last 21 years, insiders at Arena Pharmaceuticals Inc have traded over $9,243,184 worth of Arena Pharmaceuticals Inc stock and bought 78,040 units worth $252,505 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Manmeet Singh Soni und Garry Arthur Neil. On average, Arena Pharmaceuticals Inc executives and independent directors trade stock every 39 days with the average trade being worth of $3,133,387. The most recent stock trade was executed by Amit Munshi on 16 August 2021, trading 1,000 units of ARNA stock currently worth $48,190.
What does Arena Pharmaceuticals Inc do?
Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas
What does Arena Pharmaceuticals Inc's logo look like?
Complete history of Tina Nova stock trades at Adamis Pharmaceuticals Corp, Arena Pharmaceuticals Inc, Heska, Nanostring Technologies Inc, Opgen Inc, Veracyte Inc und Exagen Inc
Arena Pharmaceuticals Inc executives and stock owners
Arena Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Amit Munshi,
Director, President and Chief Executive Officer -
Vincent Aurentz,
Executive Vice President and Chief Business Officer -
Robert Lisicki,
Executive Vice President and Chief Commercial Officer -
Amit D. Munshi M.B.A.,
Pres, CEO & Director -
Vincent E. Aurentz,
Exec. VP & Chief Bus. Officer -
Dr. Christopher H. Cabell FACC, M.D., MHS,
Advisor -
Laurie D. Stelzer,
Exec. VP & CFO -
Joan Schmidt,
Exec. VP, Gen. Counsel & Sec. -
Tina Nova,
Independent Chairman of the Board -
Jennifer Jarrett,
Independent Director -
Randall Woods,
Independent Director -
Jayson Dallas,
Independent Director -
Manmeet Soni,
Independent Director -
Kieran Gallahue,
Independent Director -
Oliver Fetzer,
Independent Director -
Garry Neil,
Independent Director -
Katharine Knobil,
Director -
Joan Schmidt,
Executive Vice President, General Counsel, Secretary -
Laurie Stelzer,
Chief Financial Officer, Executive Vice President -
Patrick Malloy,
VP of Investor Relations & Corp. Communications -
Megan E. Knight,
Director of Investor Relations -
Dr. Lamine Mbow Ph.D.,
Sr. VP & Chief Scientific Officer -
Dr. Douglas A. Bakan Ph.D.,
Exec. VP of Technical Operations -
Harry F Jr Hixson,
Director -
Maurice James Mezzino,
SVP, Corporate Development -
Phillip M Schneider,
Director -
Preston Klassen,
EVP and CMO -
Steven W Spector,
EVP, General Counsel & Sec -
Scott H Bice,
Director -
Kevin Robert Lind,
Executive VP and CFO -
Christine Anna White,
Director -
Donald D Belcher,
Director -
Nawal Ouzren,
Director -
Frederick Frank,
-
Mark N Lampert,
Director -
Robert Hoffman,
SVP, Finance and CFO -
Partners L P/Ilbiotechnolog...,
-
James Laforce,
Director -
Jennifer Kathleen Bielasz,
VP, Accounting & Controller -
K A Ajit Simh,
VP, Quality Systems -
Jack Lief,
Chairman, President and CEO -
Craig Michael Audet,
SVP, Opn & Head Glob Reg Afrs -
Duke K Bristow,
Director -
Robert L Toms,
Director -
Paul W Maffuid,
VP, Pharmaceutical Development -
Joyce H Williams,
VP, Drug Development -
Partners L P/Ilbvf Inc/Ilbi...,
-
Nigel R A Beeley,
VP, Chief Chemical Officer -
Joseph F Mooney,
Chief Financial Officer -
Derek T Chalmers,
Vice President, Research -
Louis J Scotti,
VP, Marketing and Bus Dev -
Dominic P Behan,
EVP & Chief Scientific Officer -
James Edeerfield Capital Lp...,
-
Louis J Jr Lavigne,
Director -
William R Jr Shanahan,
SVP & Chief Medical Officer -
Christopher Cabell,
EVP, Head of R&D, and CMO -
Steven J Schoch,
Director -
Douglas J. Manion,
EVP Research & Development